Jade Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Jade Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($25.18M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($32.13M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($32.13M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($38.17M) | Aug 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($38.17M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.52M) | Apr 25, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($16.28M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($590.0K) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($590.0K) | Aug 13, 2025 |
| Q3 | 2024 | Mar 31, 2024 | ($23.19M) | Nov 12, 2024 |
| Q1 | 2025 | Mar 31, 2024 | ($23.19M) | Apr 25, 2025 |
| Q2 | 2024 | Mar 31, 2024 | ($23.19M) | Aug 12, 2024 |
| Q3 | 2024 | Sep 30, 2023 | ($19.56M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($19.03M) | Aug 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($19.03M) | Nov 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($16.52M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.52M) | May 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($16.52M) | Aug 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.59M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($11.99M) | Aug 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($27.40M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($27.78M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($3.39M) | Apr 25, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($14.97M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($590.0K) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($24.62M) | Apr 25, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($21.37M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($20.34M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($17.64M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.15M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($12.22M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($11.02M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.20M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.77M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($2.78M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.24M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($1.63M) | Aug 16, 2021 |